Crinetics Pharmaceuticals CRNX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $115.14M+20.1% | $102.34M-61.5% | $112.2M-64.8% | $53.73M-82.2% | $95.87M-75.8% | ||
| $1.18B-0.2% | $926.35M-15.0% | $981.39M+79.9% | $1.14B+104% | $1.18B+134% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| $1.32B+2.4% | $1.05B-23.8% | $1.12B+27.8% | $1.22B+39.2% | $1.29B+40.8% | ||
| $13.5M+6.9% | $14.3M+18.5% | $14.38M+22.8% | $14.67M+19.8% | $12.63M+6.4% | ||
| $1.4B+2.9% | $1.13B-21.5% | $1.2B+27.6% | $1.29B+37.8% | $1.36B+39.2% | ||
| $12.88M-59.3% | $22.61M+286% | $6.11M-66.6% | $38.09M+58.7% | $31.62M+10.2% | ||
| $1.27M-42.4% | $1.24M-43.2% | $1.64M-68.4% | $1.9M-55.9% | $2.21M-10.4% | ||
| $71.09M+24.0% | $85.07M+42.5% | $74.16M+38.4% | $68.4M+25.8% | $57.31M+10.7% | ||
| $120.68M+12.4% | $134.17M+22.2% | $123.86M+18.6% | $118.05M+12.7% | $107.33M+4.0% | ||
| 200M-91.3% | 200M-91.2% | 200M-88.3% | 2.3B+43.6% | 2.3B+44.2% | ||
| -$1.55B-47.3% | -$1.42B-48.9% | -$1.29B-48.5% | -$1.16B-46.5% | -$1.05B-45.6% | ||
| $1.28B+2.1% | $992.08M-25.1% | $1.07B+28.7% | $1.17B+41.0% | $1.25B+43.3% | ||
| $1.4B+2.9% | $1.13B-21.5% | $1.2B+27.6% | $1.29B+37.8% | $1.36B+39.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Crinetics Pharmaceuticals cover its short-term obligations?
- Its current ratio is 18.60 — current assets exceed current liabilities.
- Where does Crinetics Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.